F. Kabbinavar

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.

A. Mansfield, F. Kabbinavar, C. Quach, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11

F. Kabbinavar, J. Hamm, B. Nelson, 2004 .

Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation.

J. Patard, A. Belldegrun, A. Pantuck, 2012, The Journal of urology.

Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study

D. Sargent, J. Berlin, A. Grothey, 2008 .

A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).

M. Cotreau, M. Fishman, S. Srinivas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen‐independent prostate carcinoma

F. Kabbinavar, D. Vaughn, W. G. Harker, 2004, Cancer.

Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial.

F. Kabbinavar, N. Gabrail, E. Garon, 2010 .

Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis.

F. Kabbinavar, H. Hurwitz, S. Sarkar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer

Robin L. Jones, F. Kabbinavar, F. Raynaud, 2008 .

PAPILLARY RENAL CELL CARCINOMA WITH CLEAR CELLS – PATHOLOGICAL, IMMUNOHISTOCHEMICAL AND CYTOGENETIC CHARACTERISTICS OF A NOVEL ENTITY

A. Belldegrun, B. Shuch, D. Seligson, 2008 .

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

M. Rubin, J. Hainsworth, V. Miller, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Carlos Barrios, Toyoaki Hida, Keunchil Park, 2017, The Lancet.

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

A. Jubb, G. Frantz, K. Hillan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

M. Sliwkowski, F. Kabbinavar, D. Coombs, 1999, Oncogene.

First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

A. Mansfield, T. Mok, Melissa L. Johnson, 2018, The New England journal of medicine.

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

B. Karlan, F. Kabbinavar, D. Slamon, 2003, Cancer research.

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.

A. Jubb, K. Hillan, F. Kabbinavar, 2005, Journal of the National Cancer Institute.

Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma

David B Seligson, J. Leppert, A. Belldegrun, 2007, Clinical Cancer Research.

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

R. Figlin, A. Belldegrun, Su-Chun Cheng, 2014, Clinical Cancer Research.

Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma

A. Belldegrun, G. Sonn, P. N. Rao, 2013, Cancer.

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

J. Leppert, A. Belldegrun, D. Seligson, 2012, European urology.

Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy

A. Belldegrun, B. Shuch, D. Seligson, 2009, Cancer Epidemiology Biomarkers & Prevention.

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.

K. Bensalah, J. Patard, A. Belldegrun, 2008, The Journal of urology.

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy

A. Belldegrun, B. Shuch, A. Pantuck, 2010, Cancer.

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

A. Belldegrun, B. Shuch, P. N. Rao, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncology: Adrenal/Renal/Upper Tract/Bladder Fuhrman Grade Provides Higher Prognostic Accuracy Than Nucleolar Grade for Papillary Renal Cell Carcinoma

A. Belldegrun, A. Pantuck, T. Klatte, 2010 .

Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma

Amnon Zisman, David B Seligson, A. Belldegrun, 2009, Clinical Cancer Research.

Cancer‐specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989‐2005)

A. Belldegrun, B. Shuch, A. Pantuck, 2008, Cancer.

Pathobiology and prognosis of chromophobe renal cell carcinoma.

A. Belldegrun, A. Pantuck, T. Klatte, 2008, Urologic oncology.

Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.

F. Guillé, J. Patard, J. Lam, 2007, The Journal of urology.

Hypoxia-Inducible Factor 1A in Clear Cell Renal Cell Carcinoma

A. Belldegrun, D. Seligson, A. Pantuck, 2007 .

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

F. Saad, C. Higano, E. Small, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.

A. Grothey, F. Kabbinavar, P. Flynn, 2012, European journal of cancer.

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

F. Kabbinavar, N. Gabrail, E. Garon, 2016, OncoTargets and therapy.

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

F. Kabbinavar, N. Gabrail, E. Garon, 2016, OncoTargets and therapy.

Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer

F. Saad, C. Higano, E. Small, 2005 .

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

F. Kabbinavar, H. Hurwitz, Jiuzhou Wang, 2007, Journal of the National Cancer Institute.

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of surgical oncology.

D. Cella, F. Kabbinavar, H. Hurwitz, 2008, The oncologist.

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

F. Kabbinavar, C. Baum, C. Britten, 2008, Cancer Chemotherapy and Pharmacology.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

F. Kabbinavar, R. Finn, M. Fejzo, 2013, PloS one.

Salvage-Targeted Kidney Cancer Therapy in Patients Progressing on High-Dose Interleukin-2 Immunotherapy: The UCLA Experience

A. Belldegrun, A. Pantuck, J. Riss, 2013, Cancer journal.

Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.

F. Kabbinavar, J. Cherrington, D. Slamon, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Smoking negatively impacts renal cell carcinoma overall and cancer‐specific survival

A. Belldegrun, D. Seligson, A. Pantuck, 2012, Cancer.

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, The oncologist.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

L. Molinero, F. Kabbinavar, I. Braña, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

F. Hirsch, P. Bunn, W. Franklin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.

A. Belldegrun, A. Afifi, B. Shuch, 2011, The Journal of urology.

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

J. Patard, A. Belldegrun, B. Shuch, 2008, BJU international.

Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience

J. Patard, J. Bernhard, J. Lam, 2007, BJU international.

Prognostic factors for renal cell carcinoma with tumor thrombus extension.

A. Belldegrun, B. Shuch, A. Pantuck, 2007, The Journal of urology.

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

F. Kabbinavar, H. Hurwitz, S. Sarkar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

J. Hecht, F. Kabbinavar, J. Hamm, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification.

A. Belldegrun, B. Shuch, A. Pantuck, 2009, The Journal of urology.

Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.

A. Belldegrun, B. Shuch, D. Seligson, 2011, The Journal of urology.

Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.

A. Belldegrun, A. Pantuck, T. Klatte, 2010, The Journal of urology.

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

H. Christofk, F. Kabbinavar, C. Britten, 2014, Journal of Cancer Research and Clinical Oncology.

Angiogenesis and angiogenic inhibitors in renal cell carcinoma

F. Kabbinavar, R. Sawhney, 2008, Current urology reports.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

R. Figlin, K. Flaherty, S. Srinivas, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.

F. Kabbinavar, Jacob S. Thomas, 2015, Critical reviews in oncology/hematology.

Dendritic Cell–Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GM·CAIX in Immunocompetent Mouse Models

A. Belldegrun, A. Ribas, A. Pantuck, 2013, Journal of immunotherapy.

Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.

A. Belldegrun, A. Pantuck, T. Klatte, 2010, The Journal of urology.

Metastatic Colorectal Cancer for Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin Health-Related Quality of Life Impact of Bevacizumab When Combined with

D. Cella, F. Kabbinavar, H. Hurwitz, 2013 .

Phase II study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC).

F. Kabbinavar, D. Slamon, D. Reese, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

C. Obasaju, F. Kabbinavar, D. Vaughn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN).

M. Kowgier, F. Kabbinavar, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

F. Kabbinavar, H. Hurwitz, L. Saltz, 2009, Journal of Cancer Research and Clinical Oncology.

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.

Aliz R. Rao, William P. Accomando, C. Bettegowda, 2020, JAMA oncology.

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen

T. Cloughesy, F. Kabbinavar, H. Friedman, 2003, Cancer.

776PA PHASE 1/2 STUDY OF AT13387, A HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR IN COMBINATION WITH ABIRATERONE ACETATE (AA) AND PREDNISONE (P) IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) NO LONGER RESPONDING TO AA.

F. Saad, E. Gelmann, F. Kabbinavar, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells

M. Sliwkowski, F. Kabbinavar, R. Finn, 1999, Oncogene.

Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma

A. Belldegrun, N. Rao, B. Shuch, 2010, Cancer.

Re: Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification

J. Rao, A. Belldegrun, B. Shuch, 2009 .

Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma

A. Belldegrun, A. Pantuck, T. Klatte, 2007 .

Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit.

F. Hirsch, P. Bunn, W. Franklin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

J. Berlin, A. Grothey, F. Kabbinavar, 2010, Oncology.

Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.

D. Sargent, M. Buyse, J. Hecht, 2014 .

CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.

A. Belldegrun, B. Shuch, D. Seligson, 2009, The Journal of urology.

An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).

F. Kabbinavar, M. Rettig, R. Chandraratna, 2014 .

Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC)

F. Kabbinavar, H. Hurwitz, E. Holmgren, 2005 .

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

F. Kabbinavar, F. Shojaei, Bob Goodenow, 2022, Frontiers in Oncology.

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).

M. Socinski, J. Hainsworth, T. Lynch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

J. Hainsworth, V. Miller, F. Kabbinavar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).

T. Choueiri, F. Kabbinavar, D. Cho, 2012 .

Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab (Journal of the National Cancer Institute (2007) 99 (1232-1239))

F. Kabbinavar, H. Hurwitz, H. Gerber, 2008 .

Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk.

F. Kabbinavar, H. Hurwitz, A. Zurlo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab, bleeding, thrombosis, and warfarin. Author's reply

F. Kabbinavar, S. Cascinu, F. Graziano, 2003 .

Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

J. Siegfried, L. Goodglick, F. Kabbinavar, 2008 .

Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).

M. Cotreau, M. Fishman, S. Srinivas, 2011, Journal of Clinical Oncology.

Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

T. Mok, F. Kabbinavar, R. Sikorski, 2010 .

V. Miller, F. Kabbinavar, Vincent Miller, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).

L. Goodglick, F. Kabbinavar, S. Dubinett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing.

F. Kabbinavar, D. Johnson, R. Bruno, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic andMolecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma

A. Belldegrun, N. Rao, B. Shuch, 2009 .

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

E. Van Cutsem, A. Grothey, F. Kabbinavar, 2023, Cancers.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Regarding ‘Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study’

F. Kabbinavar, M. Kozloff, 2011, Oncology.

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma

E. Jonasch, F. Kabbinavar, W. Stadler, 2011, BJU international.

F. Kabbinavar, L. Fehrenbacher, D. Jablons, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

D. Cella, F. Kabbinavar, H. Hurwitz, 2008, The Oncologist.

A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial.

F. Kabbinavar, N. Gabrail, E. Garon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

a randomized Phase ii trial of the tumor vascular disrupting agent ca4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

F. Kabbinavar, N. Gabrail, E. Garon, 2016 .

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

R. Herbst, J. Nemunaitis, F. Kabbinavar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

156 METACHRONOUS BILATERAL RENAL CELL CARCINOMA: RISK ASSESSMENT, PROGNOSIS AND RELEVANCE OF THE PRIMARY-FREE INTERVAL

A. Belldegrun, A. Zisman, A. Pantuck, 2007 .

Ef ﬁ cacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

F. Kabbinavar, S. Kalmadi, E. Cronemberger, 2021 .

Ef ﬁ cacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

F. Kabbinavar, S. Kalmadi, E. Cronemberger, 2021 .

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

F. Kabbinavar, H. Hurwitz, L. Saltz, 2009, Journal of Cancer Research and Clinical Oncology.

Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).

R. Elashoff, J. Siegfried, S. Dacic, 2013 .